EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes
Portfolio Pulse from Vandana Singh
Virax Biolabs Group Limited (NASDAQ: VRAX) announced the launch of ImmuneSelect, a new portfolio within the ViraxImmune T-Cell diagnostic platform for research-use-only, aimed at evaluating adaptive immunity in post-viral syndromes. The announcement was made at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 Congress. ImmuneSelect is designed to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID, through T-Cell driven immunity evaluation. The portfolio includes peptide pools for various pathogens and recombinant antibodies targeting cytokines and biomarkers.
April 25, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Virax Biolabs announced the launch of ImmuneSelect within the ViraxImmune T-Cell diagnostic platform, targeting evaluation of adaptive immunity in post-viral syndromes. This marks a significant step towards commercializing ViraxImmune as a full in-Vitro Diagnostic product.
The launch of ImmuneSelect represents a significant development for Virax Biolabs, indicating progress in their diagnostic platform and potential for future commercialization. This could positively impact investor sentiment and VRAX's stock price in the short term, as it demonstrates the company's ongoing efforts to expand its product offerings and address significant health issues like Long COVID.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100